Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Sep 27, 2018
TickeronGET DAILY SIGNALS
Rite Aid (RAD, $1.28) Wants A Board Reshuffle

Rite Aid (RAD, $1.28) Wants A Board Reshuffle

Rite Aid wants to rejig its board, after two failed merger plans.

The  drugstore chain said Thursday that three new, independent directors will be nominated to its board and that CEO John Standley will no longer hold the title of chairman. Next month, shareholders will vote on whether to approve board nominees Robert Knowling Jr., Louis Miramontes and Arun Nayar – who, if elected, would replace current directors David Jessick, Myrtle Potter and Frank Savage. The shakedown of management comes close on the heels of failure of two buyout attempts - by the grocer Albertsons and pharmacy chain Walgreens respectively.

Walgreens, however, did buy nearly 2,000 stores from Rite Aid Corp. Following the sale of its stores, Rite Aid now has about 2,500 locations mostly on the East and West coasts, and a pharmacy benefit management business.

On Thursday, Rite Aid announced that its fiscal second-quarter earnings narrowly fell short of the consensus expectation on Wall Street.

Related Ticker: WBA

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of drug store services

Industry DrugstoreChains

Industry
Drugstore Chains
Address
108 Wilmot Road
Phone
+1 847 315-3700
Employees
331000
Web
https://www.walgreensbootsalliance.com
Interact to see
Advertisement
SSO is a 2x daily leveraged ETF (exchange-traded fund) that seeks double the daily return of the S&P 500, while XXX is a non-leveraged, passive fund blending roughly 75% S&P 500 exposure with 25% XRP, a major cryptocurrency. Both funds charge comparable fees — about 0.87% for SSO and roughly 0.85% for XXX — but their risk profiles are fundamentally different.
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
Regulatory inflection point ahead: Talphera has requested an FDA (Food and Drug Administration) Sprint Meeting to potentially close enrollment in its pivotal NEPHRO CRRT study by December 31, 2026, with feedback expected before year-end. Data catalyst pending: Topline results from the registrational trial are expected roughly four to six weeks after enrollment concludes, a defining near-term event for the stock forecast.